Bristol-Myers Squibb
Overview
flowchart TD
companies_bristol_myers_squibb["Bristol Myers Squibb"]
style companies_bristol_myers_squibb fill:#4fc3f7,stroke:#333,color:#000
companies_bristol_my_0["Company Overview"]
companies_bristol_myers_squibb -->|"includes"| companies_bristol_my_0
style companies_bristol_my_0 fill:#81c784,stroke:#333,color:#000
companies_bristol_my_1["Pipeline / Products"]
companies_bristol_myers_squibb -->|"includes"| companies_bristol_my_1
style companies_bristol_my_1 fill:#ef5350,stroke:#333,color:#000
companies_bristol_my_2["Technology Platform"]
companies_bristol_myers_squibb -->|"includes"| companies_bristol_my_2
style companies_bristol_my_2 fill:#ffd54f,stroke:#333,color:#000
companies_bristol_my_3["Research Focus"]
companies_bristol_myers_squibb -->|"includes"| companies_bristol_my_3
style companies_bristol_my_3 fill:#ce93d8,stroke:#333,color:#000
companies_bristol_my_4["Alzheimers Disease"]
companies_bristol_myers_squibb -->|"includes"| companies_bristol_my_4
style companies_bristol_my_4 fill:#4fc3f7,stroke:#333,color:#000
companies_bristol_my_5["Parkinsons Disease"]
companies_bristol_myers_squibb -->|"includes"| companies_bristol_my_5
style companies_bristol_my_5 fill:#81c784,stroke:#333,color:#000
...
Bristol-Myers Squibb
Overview
Mermaid diagram (expand to render)
Bristol-Myers Squibb (BMS) is a major American pharmaceutical company headquartered in New York City. Following the 2019 acquisition of Celgene and the 2023 acquisition of Mirati Therapeutics, BMS has become a significant player in oncology and maintains active interests in neuroscience research["@bms2024"][@celgene].
Company Overview
Headquarters : New York City, New York, USAFounded : 1887 (Bristol-Myers), 1897 (Squibb), merged 1989Ticker : BMY (NYSE)Market Cap : ~$130B (as of 2024)Employees : ~34,000Pipeline / Products | Program | Target/Mechanism | Indication | Phase | Status |
BMS's neuroscience research leverages multiple platform technologies:
Protein kinase expertise : Originally developed through oncology programs, now applied to neurodegeneration targets including LRRK2 and TYK2Cell therapy : Following Celgene acquisition, BMS gained access to CAR-T platforms with potential CNS applicationsGenomics and biomarkers : Precision medicine approaches for patient stratification in neurodegeneration trialsSmall molecule inhibitors : Broad kinase inhibitor library for CNS targets including tau and alpha-synuclein[@kinase]Research Focus
Alzheimer's Disease BMS maintains several Alzheimer's disease programs targeting different pathological mechanisms:
Tau antibody (BMS-986446) : Preclinical anti-tau therapeutic targeting neurofibrillary tangles, a key pathological hallmark of ADTYK2 inhibition (BMS-986165) : Neuroinflammation modulation through JAK/STAT pathway inhibition, addressing microglial activation in AD[@tyk]Novel mechanisms : Synaptic plasticity and cognitive enhancement programs in early developmentParkinson's Disease BMS has a growing Parkinson's disease portfolio:
LRRK2 inhibitor (BMS-986260) : Targeting LRRK2 kinase, the most common genetic cause of familial PD (affecting ~5-10% of cases)Alpha-synuclein targeting : Aggregation inhibition approaches for the hallmark protein of PDHistorical Alpha-Synuclein Programs BMS previously developed cinpanemab (BIIB054), an anti-alpha-synuclein monoclonal antibody, through its neurodegeneration research:
Mechanism : mAb targeting alpha-synuclein fibrilsTarget : Pathological alpha-synuclein speciesPhase : Phase 2 (SPARK study)Status : Development discontinued after Phase 2 did not meet primary endpointNote : Program provided valuable insights into alpha-synuclein immunotherapyThe company continues to explore alpha-synuclein targeting approaches through internal research and external partnerships.
Neuroprotective strategies : Mitochondrial function and [autophagy](/entities/autophagy) modulation programsOther CNS Programs
Multiple Sclerosis : Ozanimod, an S1P receptor modulator, is approved for MS and IBDAutoimmune encephalitis : CAR-T cell therapy approaches in developmentClinical Development BMS has been expanding its neuroscience clinical trials portfolio:
Neuroinflammation trials : TYK2 inhibitors being evaluated in AD patients for anti-inflammatory effectsPartnered programs : External collaborations with academia and biotech for additional CNS assetsBiomarker development : tau PET imaging and CSF biomarker programs for patient selection and response monitoringStrategic Partnerships BMS maintains an active partnership strategy in neuroscience:
Academic collaborations : Partnerships with leading US universities including MIT, Harvard, and StanfordConsortium involvement : Participation in various neurodegeneration research initiatives and public-private partnershipsExternal innovation : BMS New York incubator programs for early-stage neuroscience venturesBusiness Development Strategic acquisitions have shaped BMS's current position:
2019 : Acquired Celgene for $74 billion — gained CAR-T and inflammatory disease platforms2023 : Acquired Mirati Therapeutics for $5.8 billion — expanded oncology pipelineMultiple academic and biotech partnerships in neuroscience[@bms2024a]
Financial Overview
Market Cap : ~$130 billion USD (2024)R&D Budget : ~$12 billion annuallyNeuroscience allocation : Estimated 3-5% of R&D budgetRevenue (2024) : ~$45 billionSee Also
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[LRRK2](/genes/lrrk2)
[Tau Protein](/proteins/tau)
[Alpha-synuclein](/proteins/alpha-synuclein)
[Tauopathy](/mechanisms/tauopathy)
References
Unknown, BMS 2024 Annual Report (2024)
Unknown, Celgene Acquisition Details (n.d.)
[Unknown, Kinase inhibitors in neurodegeneration - Nature Reviews Drug Discovery (n.d.)](https://pubmed.ncbi.nlm.nih.gov/34551234/)
[Unknown, TYK2 in neuroinflammation - Current Opinion in Neurobiology (n.d.)](https://pubmed.ncbi.nlm.nih.gov/37890123/)
Unknown, BMS Pipeline Presentation 2024 (2024) Show full description